Volume | 952,636 |
|
|||||
News | - | ||||||
Day High | 29.11 | Low High |
|||||
Day Low | 27.305 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Stevanato Group SpA | STVN | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
28.50 | 27.305 | 29.11 | 28.40 | 28.86 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,700 | 952,636 | $ 27.98 | $ 26,658,828 | - | 23.00 - 36.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:16:44 | 5 | $ 28.99 | USD |
Stevanato Group SpA Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.4B | 295.54M | - | 1B | 142.85M | 0.48 | 58.80 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Stevanato News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical STVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 29.16 | 29.82 | 27.305 | 29.16 | 235,928 | -0.4488 | -1.54% |
1 Month | 26.48 | 33.49 | 25.52 | 30.52 | 549,818 | 2.23 | 8.43% |
3 Months | 30.27 | 34.73 | 25.52 | 30.93 | 364,308 | -1.56 | -5.15% |
6 Months | 33.98 | 34.73 | 23.00 | 29.34 | 333,987 | -5.27 | -15.51% |
1 Year | 27.71 | 36.30 | 23.00 | 29.77 | 325,679 | 1.00 | 3.61% |
3 Years | 16.65 | 36.30 | 13.355 | 23.05 | 359,664 | 12.06 | 72.44% |
5 Years | 16.65 | 36.30 | 13.355 | 23.05 | 359,664 | 12.06 | 72.44% |
Stevanato Description
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America. |